Carvedilol attenuates experimentally induced silicosis in rats via modulation of P-AKT/mTOR/TGFβ1 signaling

Rees, 2007, Silica, silicosis and tuberculosis, Int. J. Tuberc. Lung Dis., 11, 474 Leung, 2012, Silicosis, Lancet (London, England), 379, 2008, 10.1016/S0140-6736(12)60235-9 Rosenbloom, 2017, Human fibrotic diseases: current challenges in fibrosis research, Methods Mol. Biol., 1627, 1, 10.1007/978-1-4939-7113-8_1 Carneiro P. J., Clevelario A. L., Padilha G. A., Silva J. D., Kitoko J. Z., Olsen P. C., et al. Bosutinib therapy ameliorates lung inflammation and fibrosis in experimental silicosis. Front. Physiol.. 2017; 8:159. Ooi G. C., Tsang K. W., Cheung T. F., Khong P. L., Ho I. W., Ip M. S., et al. Silicosis in 76 men: qualitative and quantitative CT evaluation--clinical-radiologic correlation study. Radiology. 2003; 228(3):816–25. . Ferreira T. P., de Arantes A. C., do Nascimento C. V., Olsen P. C., Trentin P. G., Rocco P. R., et al. IL-13 immunotoxin accelerates resolution of lung pathological changes triggered by silica particles in mice. J. Immunol.. 2013; 191 (10):5220–9. Kuo, 1992, Rapamycin selectively inhibits interleukin-2 activation of p 70 S6 kinase, Nature, 358, 70, 10.1038/358070a0 Lawrence, 2018, The role of the mammalian target of rapamycin (mTOR) in pulmonary fibrosis, Int. J. Mol. Sci., 19, 10.3390/ijms19030778 Kulkarni A. A., Thatcher T. H., Olsen K. C., Maggirwar S. B., Phipps R. P., Sime P. J. PPAR-gamma ligands repress TGFbeta-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. PLoS One. 2011; 6(1):e15909. Shimada, 2012, Carvedilol reduces the severity of atherosclerosis in apolipoprotein E-deficient mice via reducing superoxide production, Exp. Biol. Med. (Maywood), 237, 1039, 10.1258/ebm.2012.012022 Budni, 2013, Wilhelm Filho D. Carvedilol enhances the antioxidant effect of vitamins E and C in chronic Chagas heart disease, Arq. Bras. Cardiol., 101, 304 Tian X., Zhao C., Guo J., Xie S., Yin F., Huo X., et al. Carvedilol attenuates the progression of hepatic fibrosis induced by bile duct ligation. Biomed. Res. Int.. 2017; 2017:4612769. El-Demerdash, 2017, Antifibrotic effects of carvedilol and impact of liver fibrosis on carvedilol pharmacokinetics in a rat model, Eur. J. Drug Metab. Pharmacokinet., 42, 767, 10.1007/s13318-016-0391-9 Hemmati, 2008, A comparative study of grape seed extract and vitamin E effects on silica-induced pulmonary fibrosis in rats, Pulm. Pharmacol. Ther., 21, 668, 10.1016/j.pupt.2008.04.004 Amirshahrokhi, 2016, Carvedilol attenuates paraquat-induced lung injury by inhibition of proinflammatory cytokines, chemokine MCP-1, NF-κB activation and oxidative stress mediators, 88, 144 Abdelaziz, 2016, Tadalafil reduces airway hyperactivity and protects against lung and respiratory airways dysfunction in a rat model of silicosis, Int. Immunopharmacol., 40, 530, 10.1016/j.intimp.2016.10.007 Schierwagen, 1990, Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity, 23, 179 Ferreira, 2007, Tumor growth, angiogenesis and inflammation in mice lacking receptors for platelet activating factor (PAF), Life Sci., 81, 210, 10.1016/j.lfs.2007.05.003 Xu H., Yang F., Sun Y., Yuan Y., Cheng H., Wei Z., et al. A new antifibrotic target of Ac-SDKP: inhibition of myofibroblast differentiation in rat lung with silicosis. PLoS One. 2012; 7(7):e40301. Song L., Weng D., Dai W., Tang W., Chen S., Li C., et al. Th17 can regulate silica-induced lung inflammation through an IL-1beta-dependent mechanism. J. Cell. Mol. Med.. 2014; 18(9):1773–84. Shimada A., Kohara Y., Naota M., Kobayashi Y., Morita T., Inoue K., et al. Pathological study of chronic pulmonary toxicity induced by intratracheally instilled Asian sand dust (Kosa): possible association of fibrosis with the development of granulomatous lesions. Folia Histochem. Cytobiol.. 2015; 53(4):294–306. Fubini, 2003, Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis, Free Radic. Biol. Med., 34, 1507, 10.1016/S0891-5849(03)00149-7 Yucesoy, 2002, Cytokine polymorphisms in silicosis and other pneumoconioses, Mol. Cell. Biochem., 234-235, 219, 10.1023/A:1015987007360 Yeo, 2010, Asian sand dust enhances rhinovirus-induced cytokine secretion and viral replication in human nasal epithelial cells, Inhal. Toxicol., 22, 1038, 10.3109/08958378.2010.516282 Rahat M. A., Coffelt S. B., Granot Z., Muthana M., Amedei A. Macrophages and neutrophils: regulation of the inflammatory microenvironment in autoimmunity and cancer. Mediat. Inflamm.. 2016; 2016:5894347. Gulati, 2015, Asbestosis and environmental causes of usual interstitial pneumonia, Curr. Opin. Pulm. Med., 21, 193 Saxton, 2017, mTOR signaling in growth, metabolism, and disease, Cell, 168, 960, 10.1016/j.cell.2017.02.004 Chung, 1992, Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases, Cell, 69, 1227, 10.1016/0092-8674(92)90643-Q Liu Z. G., Tang J., Chen Z., Zhang H., Wang H., Yang J., et al. The novel mTORC1/2 dual inhibitor INK128 enhances radiosensitivity of breast cancer cell line MCF-7. Int. J. Oncol.. 2016; 49(3):1039–45. Weichhart, 2015, Regulation of innate immune cell function by mTOR, Nat. Rev. Immunol., 15, 599, 10.1038/nri3901 Linke M., Pham H. T., Katholnig K., Schnoller T., Miller A., Demel F., et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat. Immunol.. 2017; 18(3):293–302. Syed F., Sherris D., Paus R., Varmeh S., Singh S., Pandolfi P. P., et al. Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor. Am. J. Pathol.. 2012; 181(5):1642–58. Citrin D. E., Prasanna P. G. S., Walker A. J., Freeman M. L., Eke I., Barcellos-Hoff M. H., et al. Radiation-induced fibrosis: mechanisms and opportunities to mitigate. Report of an NCI workshop, September 19, 2016. Radiat. Res.. 2017; 188(1):1–20. Mu, 2012, Non-Smad signaling pathways, Cell Tissue Res., 347, 11, 10.1007/s00441-011-1201-y Chung E. J., Sowers A., Thetford A., McKay-Corkum G., Chung S. I., Mitchell J. B., et al. Mammalian target of rapamycin inhibition with rapamycin mitigates radiation-induced pulmonary fibrosis in a murine model. Int. J. Radiat. Oncol. Biol. Phys.. 2016; 96(4):857–66. Mercer P. F., Woodcock H. V., Eley J. D., Plate M., Sulikowski M. G., Durrenberger P. F., et al. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax. 2016; 71(8):701–11. Chang W., Wei K., Ho L., Berry G. J., Jacobs S. S., Chang C. H., et al. A critical role for the mTORC2 pathway in lung fibrosis. PLoS One. 2014; 9(8):e106155. Hamdy, 2012, New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage, Toxicol. Appl. Pharmacol., 261, 292, 10.1016/j.taap.2012.04.012 El-Wakeel S. A., Rahmo R. M., El-Abhar H. S. Anti-fibrotic impact of carvedilol in a CCl-4 model of liver fibrosis via serum micro RNA-200a/SMAD7 enhancement to bridle TGF-beta 1/EMT track. Sci. Rep.. 2018; 8(1):14327. Zhang, 2017, MiR-200a modulates TGF-beta 1-induced endothelial-to-mesenchymal shift via suppression of GRB2 in HAECs, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 95, 215, 10.1016/j.biopha.2017.07.104 Kotlyar, 2002, Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma, J. Heart Lung Transplant, 21, 1290, 10.1016/S1053-2498(02)00459-X